Perceptive Advisors - AMICUS THERAPEUTICS INC ownership

AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 237 filers reported holding AMICUS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.

Quarter-by-quarter ownership
Perceptive Advisors ownership history of AMICUS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$336,745,870
-3.1%
27,692,917
+0.1%
11.23%
+11.7%
Q2 2023$347,446,237
+13.3%
27,662,9170.0%10.06%
+11.0%
Q1 2023$306,781,750
-9.1%
27,662,917
+0.1%
9.06%
-4.4%
Q4 2022$337,520,017
+18.1%
27,642,917
+1.0%
9.48%
+14.3%
Q3 2022$285,773,000
-1.1%
27,372,917
+1.8%
8.29%
-8.3%
Q2 2022$288,858,000
+10.7%
26,895,532
-2.4%
9.05%
+73.1%
Q1 2022$260,954,000
-57.5%
27,555,845
-48.1%
5.23%
+10.5%
Q4 2021$613,524,000
+141.9%
53,118,886
+100.0%
4.73%
+28.4%
Q3 2021$253,643,000
-43.1%
26,559,443
-42.6%
3.68%
+27.3%
Q2 2021$445,780,000
+97.4%
46,242,658
+102.3%
2.90%
+1.4%
Q1 2021$225,870,000
-61.0%
22,861,329
-9.0%
2.86%
-54.1%
Q4 2020$579,837,000
+63.5%
25,112,048
-0.0%
6.22%
+20.2%
Q3 2020$354,723,000
-6.6%
25,122,048
-0.2%
5.18%
-15.8%
Q2 2020$379,750,000
+63.2%
25,182,3640.0%6.15%
+1.6%
Q1 2020$232,685,000
-4.9%
25,182,364
+0.2%
6.06%
+24.6%
Q4 2019$244,789,000
+24.0%
25,132,364
+2.1%
4.86%
-8.5%
Q3 2019$197,369,000
-26.5%
24,609,700
+14.4%
5.32%
-13.7%
Q2 2019$268,438,000
-8.8%
21,509,486
-0.6%
6.16%
-25.8%
Q1 2019$294,297,000
+53.5%
21,639,486
+4.4%
8.30%
+13.8%
Q4 2018$191,701,000
-23.4%
20,724,424
+0.1%
7.30%
+9.1%
Q3 2018$250,196,000
-20.0%
20,694,424
+3.3%
6.69%
-18.4%
Q2 2018$312,782,000
+3.9%
20,024,4240.0%8.20%
-2.8%
Q1 2018$301,167,000
+17.0%
20,024,424
+11.9%
8.44%
-1.1%
Q4 2017$257,417,000
-52.3%
17,888,597
-50.0%
8.53%
-17.2%
Q3 2017$539,520,000
+209.8%
35,777,194
+106.8%
10.30%
+17.5%
Q2 2017$174,178,000
+41.2%
17,296,6720.0%8.76%
+24.8%
Q1 2017$123,325,000
+43.5%
17,296,6720.0%7.02%
+14.9%
Q4 2016$85,964,000
-17.7%
17,296,672
+22.5%
6.11%
-9.3%
Q3 2016$104,463,000
+25.5%
14,116,644
-7.4%
6.74%
+16.9%
Q2 2016$83,207,000
-35.4%
15,239,4440.0%5.77%
-48.9%
Q1 2016$128,773,000
-12.9%
15,239,4440.0%11.30%
+3.3%
Q4 2015$147,823,000
-57.9%
15,239,444
-47.2%
10.94%
-22.1%
Q3 2015$351,266,000
+71.9%
28,878,888
+100.0%
14.03%
+14.1%
Q2 2015$204,318,000
+30.1%
14,439,4440.0%12.30%
+0.8%
Q1 2015$157,101,000
+30.8%
14,439,4440.0%12.21%
+21.2%
Q4 2014$120,136,000
+63.6%
14,439,444
+17.0%
10.08%
+27.8%
Q3 2014$73,420,000
+78.1%
12,339,4440.0%7.88%
+95.0%
Q2 2014$41,214,000
+1960.7%
12,339,444
+1177.0%
4.04%
+1825.2%
Q1 2014$2,000,000966,3000.21%
Other shareholders
AMICUS THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Palo Alto Investors LP 10,524,022$127,972,10812.11%
Perceptive Advisors 27,692,917$336,745,87011.23%
Redmile Group, LLC 16,944,621$206,046,5919.80%
Finepoint Capital LP 1,489,025$18,106,5449.02%
CM Management, LLC 450,000$5,472,0005.81%
Avoro Capital Advisors LLC 27,400,000$333,184,0005.20%
MPM BioImpact LLC 716,139$8,708,2502.32%
Artal Group S.A. 4,062,567$49,4012.12%
SECTORAL ASSET MANAGEMENT INC 803,464$9,770,1221.90%
GREAT POINT PARTNERS LLC 857,000$10,421,1201.90%
View complete list of AMICUS THERAPEUTICS INC shareholders